

Report for Study xxxx

STUDY TITLE)

Study Number: xxxx

TESTING FACILITY:

SIGNATURES

I approve the report and confirm that the study was conducted in conformance with applicable Drug Safety Research & Development Groton standard operating procedures.

xxx, BS
Senior Associate Scientist

xxx, BA
Senior Scientist

xxx, MS
Senior Principal Scientist

For signatures see Signature Page.

GLP COMPLIANCE STATEMENT

This study was conducted as a non-regulated study.

STUDY TITLE

ABSTRACT

First paragraph of abstract.

STUDY TITLE

1. INTRODUCTION

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

2. STUDY OBJECTIVES

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

3. MATERIALS AND METHODS

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

3.1. In vitro human whole blood soluble cytokine release assay

Aenean nec lorem. In porttitor. ([Wing et al, 1995](#)): Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

| | Concentrations Tested |
|---|-----------------------------|
| Aenean nec lorem. In porttitor. | 1000, 100, 10, 1 μ g/mL |
| Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. | 100, 10, 1 μ g/mL |
| Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. | 50, 5 μ g/mL |
| Aenean nec lorem. In porttitor. | 1000 pg/mL |
| Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. | 100 μ g/mL |
| Aenean nec lorem. In porttitor. | |

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

3.2. In vitro human PBMC solid phase cytokine release assay

Pellentesque habitant morbi tristique senectus et netus et malesuada ([Findlay et al, 2010](#)):

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

| | Concentrations Tested |
|---|------------------------|
| Aenean nec lorem. In porttitor. | 1000, 100, 10, 1 µg/mL |
| Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. | 100, 10, 1 µg/mL |
| Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. | 50, 5 µg/mL |
| Aenean nec lorem. In porttitor. | 1000 pg/mL |
| Aenean nec lorem. In porttitor. Aenean nec lorem. In porttitor. | 100 µg/mL |
| Aenean nec lorem. In porttitor. | |

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

4. RESULTS

4.1. Assay

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. [Table 2](#) (Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. [Table 3](#)). Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc..

4.2. Release assay

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. [Table 4](#) (Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. [Table 5](#)). Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc..

Figure 1 is also inserted into this document as an orphaned bookmark:

Figure 1. Test Figure



5. DISCUSSION/CONCLUSIONS

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.

Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Aenean nec lorem. In porttitor. Donec laoreet nonummy augue.

Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy.

6. REFERENCES

Wing MG, Waldmann H, Isaacs J, et al. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci. 995;2:183-90.

Findlay L, Eastwood D, Stebbings R, et al. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci. 2010;352:1-12.

7. ARCHIVING

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci.

Table 1. Concentration and Level

| PF Number | Concentration mg/mL | AAAAA EU/mg |
|-----------|---------------------|-------------|
| PF-a | 111.54 | 0.1111111 |

Table 2. Concentrations (pg/mL) in Soluble Phase Assay (Mean of Duplicate Samples)

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

**Table 2. Concentrations (pg/mL) in Soluble Phase Assay (Mean of Duplicate Samples)
(continued)**

| | Donor 1 | | | Donor 2 | | |
|-----------------|---------|------|-------|---------|------|-------|
| | ABC-γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Donor 4 | | | | Donor 3 | | |
| | ABC -γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

Table 3. Fold Change and Percent AAA Control in Concentrations (Soluble Phase Assay)

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

Table 3. Fold Change and Percent AAA Control in Concentrations (Soluble Phase Assay) (continued)

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DED served as negative controls.

**Table 3. Fold Change and Percent AAA Control in Concentrations (Soluble Phase Assay)
(continued)**

| | Donor 1 | | | Donor 2 | | |
|-----------------|---------|------|-------|---------|------|-------|
| | ABC-γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Donor 4 | | | | Donor 3 | | |
| | ABC -γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

**Table 3. Fold Change and Percent AAA Control in Concentrations (Soluble Phase Assay)
(continued)**

| | Donor 1 | | | Donor 2 | | |
|-----------------|---------|------|-------|---------|------|-------|
| | ABC-γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Donor 4 | | | | Donor 3 | | |
| | ABC -γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

Table 4. Concentrations (pg/mL) in Solid Phase Assay (Mean of Duplicate Samples)

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

Table 4. Concentrations (pg/mL) in Solid Phase Assay (Mean of Duplicate Samples)
(continued)

| | Donor 1 | | | Donor 2 | | |
|-----------------|---------|------|-------|---------|------|-------|
| | ABC-γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Donor 4 | | | | Donor 3 | | |
| | ABC -γ | AB-6 | RRR-α | ABC -γ | AB-6 | RRR-α |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |
| Mauris et orci. | 100 | 100 | 100 | | 100 | 100 |

AAA = aaa; AAA = AAA; anti-AAA A = awertfa; CCC = asdfasddf.

SDF and afg DDD anti-human DDD were included as positive controls.

Anti-EEE TMDS anti-RRR DG antibody and DFD served as negative controls.

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay)

| | Donor 805 | | | | | | | | |
|-----------------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-----------|
| | AAA-γ | | | AA-6 | | | AAA-α | | |
| | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

| | Donor 805 | | | | | | | | |
|-----------------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-----------|
| | AAA-γ | | | AA-6 | | | AAA-α | | |
| | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

| | Donor 805 | | | | | | | | |
|-----------------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-----------|
| | AAA-γ | | | AA-6 | | | AAA-α | | |
| | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

| | Donor 805 | | | | | | | | |
|-----------------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-----------|
| | AAA-γ | | | AA-6 | | | AAA-α | | |
| | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

| | Donor 805 | | | | | | | | |
|-----------------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-----------|
| | AAA-γ | | | AA-6 | | | AAA-α | | |
| | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

| | Donor 805 | | | | | | | | |
|-----------------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-----------|
| | AAA-γ | | | AA-6 | | | AAA-α | | |
| | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath | Fold Change | % CD28 | % Campath |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Mauris et orci. | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |

Subtext

Table 5. Fold Change, Percent AAA and Percent Campath (Solid Phase Assay) (continued)

Subtext

Appendix 1. Study Details

| Text/Table/Figure Number | Laboratory Notebook Number & Page(s) and/or Supplemental Notebook Number & Page(s) |
|--------------------------|--|
| Data, Text | eWorkbook 55555-5 version 2 |

| Laboratory Notebook | Notebook Owner | Notebook Location |
|---------------------|----------------|-------------------|
| eWorkbook | Scientist | xxxxxxxx |

Xxx xxxxxxxxxxxxxxxx xxxx xx xxxxxxxxx xxx xxxxxxxxxxxxx xx xxxxxxx xxxxxxxxx